The East-West Bio Brief

FDA decision day for Akeso's ivonescimab; BioNTech buys voucher; Intellia deadline set

11 min Listen to the original Episode page
FDA ApprovalOncologyBiotechCRISPRClinical Trials

Summary

Basil Lui and AI co-host Ning discuss the November 14 FDA decision deadline for Akeso's ivonescimab, a PD1/VEGF bispecific licensed to Summit Therapeutics. They analyze the HARMONi trial results, noting progression-free survival benefits but missed statistical significance in overall survival, complicated by a trial population weighted 60% toward Asian patients. The episode contrasts Akeso's path with BioNTech's purchase of a priority review voucher and highlights Intellia's upcoming March 2027 deadline for its CRISPR therapy lonvo-z.

Episode sections

  1. 0:04 – 0:47

    Intro and AI-voice disclosure

    Basil Lui introduces the episode topic: the FDA deadline for ivonescimab. Ning introduces herself as an AI co-host, clarifying that Basil is the real person and the content is personal views, not advice.

  2. 0:47 – 1:58

    Ivonescimab's FDA decision day

    Ning states that November 14 is the FDA target date for ivonescimab, a bispecific drug invented by Akeso and licensed to Summit Therapeutics. As of early Saturday morning Singapore time, no decision had been announced by the companies or FDA.

  3. 1:58 – 3:06

    The HARMONi trial results

    Basil explains ivonescimab is a bispecific blocking PD1 and VEGF. Ning details the HARMONi trial results: progression-free survival was met (HR 0.52), but overall survival missed statistical significance at the main analysis (HR 0.79).

  4. 3:06 – 3:47

    The East-West patient split

    Ning notes that of 438 patients, roughly 60% were from Asia. Basil mentions the drug is already approved in China for over 100,000 patients. Ning highlights the FDA's challenge in evaluating a trial weighted towards Asian patients with nominal Western survival data.

  5. 3:47 – 5:01

    Akeso's story

    Ning recounts Akeso's history: founded in 2012 with $3 million, now has 4,500 staff, 8 marketed treatments, and 2025 revenue above 3 billion yuan. Basil cites Jeffrey Kui from Bloomberg, noting Akeso's unique success in global studies and a China-only trial presented at ASCO.

  6. 5:01 – 5:38

    What each outcome would mean

    Ning outlines potential FDA outcomes: approval (first PD1xVEGF bispecific in US), complete response letter, or missed deadline. She notes AstraZeneca's $2 billion equity investment in Summit in October.

  7. 5:38 – 6:33

    BioNTech and a rival route

    Ning reports BioNTech paid $205 million for an FDA priority review voucher, likely for pumotolimab, a bispecific acquired from BioThes. This contrasts with Akeso's contested approval path.

  8. 6:33 – 10:42

    Lonvo-z and in-body CRISPR

    Ning announces the March 10, 2027 FDA deadline for Intellia's lonvo-z, a one-time CRISPR treatment for hereditary angioedema. Basil notes an 89% attack reduction in 93 patients and the significance of it being the first in-body CRISPR edit, despite past safety pauses.

Assets discussed

AssetKindStanceContext
SanofiSNYequityneutralTogether with a $50 million private placement from Sanofi, it expects to raise $225 million before costs, according to its company press release.

“Stance” is how the speakers talked about the asset, not a recommendation.

Claims worth verifying

November 14 is the FDA's target date for ivonescimab.

Ning ·0:47

How to verify: FDA database for ivonescimab NDA action date; Summit Therapeutics press releases. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.

Ivonescimab was invented by Akeso and licensed to Summit Therapeutics.

Ning ·0:47

How to verify: Akeso and Summit Therapeutics partnership agreements filed with SEC or company websites. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.

Primary source

As of early Saturday morning Singapore time, no FDA decision had been announced.

Ning ·1:07

How to verify: News archives from November 14, 2026; FDA press releases. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.

Ivonescimab blocks PD1 and VEGF.

Basil Lui ·1:11

How to verify: FDA briefing documents for ivonescimab; scientific literature on the drug's mechanism. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.

The HARMONi trial had 438 patients.

Basil Lui ·1:57

How to verify: HARMONi trial clinical study results published in journals or filed with FDA/EMA. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.

Progression-free survival hazard ratio was 0.52.

Basil Lui ·2:17

How to verify: HARMONi trial primary endpoint results in FDA briefing documents or Summit Therapeutics presentations. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.

Overall survival hazard ratio at main analysis was 0.79 and not statistically significant.

Ning ·2:24

How to verify: HARMONi trial results announced in May 2025; Summit Therapeutics investor presentations. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.

Western patients had a median follow-up of 9.2 months at the main analysis.

Basil Lui ·2:42

How to verify: HARMONi trial data cut-off details in FDA briefing documents. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.

Updated analysis from June showed an overall survival hazard ratio of 0.76.

Unidentified speaker (UNKNOWN) ·2:50

How to verify: Summit Therapeutics updates or FDA briefing documents referencing June analysis. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.

Akeso was founded in 2012 with $3 million from local investors.

Ning ·3:47

How to verify: Akeso corporate history on its website; Bloomberg Business Week article cited. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.

Do your own research

  • Verify the FDA decision status for ivonescimab via the FDA's official drug approval database or Summit Therapeutics press releases.
  • Review the full HARMONi trial data publication in peer-reviewed journals to assess the statistical significance of overall survival results.
  • Check Akeso's latest financial filings (e.g., HKEX announcements or SEC filings if applicable) for revenue figures and pipeline updates.
  • Confirm BioNTech's acquisition of the priority review voucher and the specific indication for pumotolimab through BioNTech's investor presentations.
  • Examine Intellia Therapeutics' clinical trial updates for lonvo-z, specifically the safety data and long-term follow-up results.
  • Assess the demographic breakdown of the HARMONi trial to understand the generalizability of results to Western populations.
  • Check for any conflicts of interest or financial disclosures from the speakers regarding holdings in Akeso, Summit, BioNTech, or Intellia.
Full transcriptexpand
0:04
Basil Lui: Today is the FDA's deadline for Ivonescimap, a lung cancer drug invented in China and tested mostly on patients in Asia. Its key trial hit one main goal and missed the other. Is that enough to reach American patients? I'm Baso Basil Louis, investing globally from Singapore with an
0:24
Basil Lui: Asia angle. This is the East West Bio. Brief, Biotech and Beyond, for Saturday, November 14th.
0:33
Ning: And I'm Ning, Basil's AI co-host. Both our voices are AI clones, but Basil is the real person behind this show. Personal views, not investment advice.
0:47
Ning: Saturday, November 14th is the FD. FDA's target date to decide on EvoNesimap. It was invented by Ake So in Chinese, Kang Feng Shongwu, and licensed to summit therapeutics for markets including the US, Europe and Japan. When we checked early on Saturday morning,
1:07
Ning: Singapore Time, neither the companies nor the FDA had announced a decision.
1:11
Basil Lui: Evonis CMAP is one antibody that does two jobs. So it's called a bispecific. It blocks PD1, a brick that tumors use to switch off the immune system, and it blocks VEGF, a signal tumors use to grow
1:31
Basil Lui: new blood vessels. Summit wants to use it with chemotherapy in a type of lung cancer with an EG. EGFR mutation after earlier treatment with an EGFR blocking pill. In the main trial, that meant a third-generation pill such as Osimotinip.
1:51
Ning: So, Basil, what does the evidence actually show? Shook.
1:57
Basil Lui: The application rests on Harmony, a global phase 3 trial of 438 patients, and it has two main goals. The first is progression free survival, which is how long patients live before the cancer grows. That one was met. Adding IvoneskiMap cut the risk of the cancer
2:17
Basil Lui: growing or death by 48%, a hazard ratio of 0.52.
2:23
Unidentified speaker (UNKNOWN): The
2:24
Ning: second main goal is overall survival, and that's the highest. hard part. At the main analysis announced in May 2025, the survival hazard ratio was 0.79, which was not statistically significant. Summit has said the FDA told it that a statistically significant survival benefit is needed to support approval in this setting.
2:42
Basil Lui: Summit's answer is time. At that main analysis, Western patients had been followed for a median of only 9.2 months.
2:50
Unidentified speaker (UNKNOWN): An
2:50
Basil Lui: updated analysis from June this year showed a hazard ratio of 0.76, both overall and in Western patients. But those later results are labeled nominal, which means they don't count as meeting the trial's preset bar.
3:06
Unidentified speaker (UNKNOWN): And
3:06
Ning: this is where our East-West question comes in. Of the 438 patients, 165 were from Western countries, so roughly 6%. in 10 were enrolled in Asia. The FDA has to decide whether a trial weighted towards Asian patients plus a later look at the Western
3:25
Ning: ones is enough.
3:27
Basil Lui: In China, the drug already has a track record. It was first approved there in May 2024 for this kind of lung cancer based on a trial run. only in China, and Akezo says more than 100,000 patients have been treated with it their outside trials.
3:47
Ning: AKeso's own story is a striking one. Bloomberg Business Week reports that it was founded in 2012 in Zhongshan, in southern China, with 3 million US dollars from local investors. starting in a 20 square meter office.
4:06
Ning: Today it has about 4,500 staff, 8 treatments on the market in China, more than 50 drugs in development, and 2025 revenue above 3 billion yuan.
4:22
Basil Lui: Bloomberg also quotes Kui Kui, Jeffrey's head of Asia Healthcare research. saying no other Chinese company has shown consistent results across Chinese and global studies for a major disease treatment. In her words, a queso was the first in that regard. And this year, an AQSO trial run only in
4:42
Basil Lui: China was presented at the plenary session of ASCO, ESCO, the big American cancer meeting. Bloomberg says it was the first trial. conducted only in China to get that slot in the society's 61 year history. So, Ning, what would each outcome mean?
5:01
Unidentified speaker (UNKNOWN): If
5:01
Ning: the FDA approves, Biospace notes it could be the first PD1x VEGF bi-specific on the US market, and the label will show how much weight the agency put on the later survival data. If it sends what's called a complete response, letter, our reading is that strong progression free survival wasn't enough when survival was the bar the
5:20
Ning: FDA had set. The agency can also simply miss its date. Western interest is already there. AstraZeneca completed a $2 billion equity investment in Summit in October.
5:33
Basil Lui: I have no personal holding in any of the companies mentioned today.
5:38
Ning: On Friday, we looked at a rival route to American patients for the same kind of drug. Biotech is paying 205 million US dollars for an FDA priority review voucher. And Fierce Pharma's analysis is that the likely use is Pumitamid, a two-in-one antibody that blocks PDL-1 One and
5:57
Ning: VEGF, which biotech got by buying China's biotheus biotheas in China. Chinese Pumice.
6:04
Basil Lui: So two Chinese invented drugs of the same class, one going through a Western Partners application and a contested survival result, the other bought outright by a European drug maker. On Monday, our weekly takes today's decision into our uh where do the patients come from
6:24
Basil Lui: threat and the bigger question of when the FDA accepts trials run mostly in Asia.
6:33
Ning: One more FDA date for the diary. March 10th, 2027. That's the deadline for Lonvosi from Intelli Therapeutics for hereditary angioedema, a rare inherited disease that causes sudden painful. swelling attacks. Lonvo Z
6:53
Ning: is a one-time infusion that uses CRISPR gene editing inside the liver to switch off the gene for precalicrine, a protein that drives those attacks.
7:04
Basil Lui: At this week's American allergy meeting, ACAAI IntelliA Earlier
7:09
Unidentified speaker (UNKNOWN): said
7:09
Basil Lui: in a company press release that across 93 patients given a single dose, attacks a tax fell. by 89% over up to 4 years. Nature notes that if it's approved, it would be the first CRISPR medicine given directly inside the body, but also that editing inside the body offers no
7:29
Basil Lui: chance to screen out unwanted edits, and that the FDA paused two other IntelliA studies last year after a patient died. That hole was lifted this year.
7:40
Ning: In Shanghai, Argo biopharma in Chinese, Borwang Jiyao, is targeting the same protein a different way. Its drug, BW20805, is an RNA silencer, which turns down the liver's production of precalicrine with injections every 12 or 24 weeks. In a small phase 2 two trial of 24 patients,
8:00
Ning: Argo reports attacks fell by 83 to 9%. 96% depending on dose, and the FDA has given it fast track status.
8:08
Basil Lui: A permanent edit or a dose a few times a year that can be stopped? That's a question for our One Science Many Rule Books thread on gene and cell medicine, and we'll come back to it in December.
8:23
Ning: One deal from the past day. Winward Winwood Bio.
8:27
Ning: based in Basel, Switzerland, priced its NASDAQ share sale on Thursday at $17 a share. Together with a $50 million private placement from Sanofi, it expects to raise $225 million
8:43
Ning: before costs, according to its company press release.
8:47
Basil Lui: Both of its lead drugs were licensed from China. WIN378 is a long-acting antibody against TSLP, an alarm signal that sets off inflammation in the airways, and it's being tested in asthma and in COPD, a chronic lung disease.
9:07
Basil Lui: It came from Kalun Biotech and Harbor Biome. WINO27Blocks, Win O27 blocks, TSLP, and a second inflammation signal, IL13, and came from Qine's Therapeutics. Neither is approved yet.
9:23
Ning: Invented in China, developed outside it by a European company, and funded on an American exchange. That's our running thread on China as Big Pharma's Farmer's new RD lab.
9:36
Basil Lui: So back to the opening. Yvonne SIMUP's global trial clearly slowed the cancer. The open question is whether a survival result that missed its preset bar plus later results labeled nominal is enough for the FDA.
9:56
Basil Lui: We won't guess the answer.
9:58
Ning: Whatever the agency decides, it goes into Monday's weekly or on where the patients come from. And keep March 10th in mind for the first in-body CRISPR decision.
10:09
Basil Lui: If you find this brief useful, follow the East West Biobrief on Spotify or Apple Podcasts.
10:16
Ning: And for the transcripts and sources, subscribe to our newsletter on LinkedIn, also called the East West Biobrief. Bio Brief. It goes out every Monday with our weekly. roundup. That's today's brief. The key sources are in the show notes. See you tomorrow.
This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.

More from The East-West Bio Brief

The East-West Bio Brief

Daily, Sun 15 Nov: Beijing adds 107 drugs, Europe says yes. Who wins?

Episode discussion: China adds 107 drugs to insurance list; Europe backs lung cancer treatments; FDA decision pending for ivonescimab

Speakers’ claims: Speakers report that China's National Healthcare Security Administration added 107 new drugs to its 2026 National Reimbursement Drug List, including a record 51 Class 1 innovative drugs. JW Therapeutics' CAR-T therapy and Novo Nordisk's insulin-semaglutide combination were highlighted as notable additions. In Europe, the EMA's CHMP backed Hansoh's aumolertinib and Innovent's sintilimab for lung cancer. Meanwhile, the FDA's decision on Akeso's ivonescimab remained pending as of the episode's recording. The speakers also discussed US regulatory restrictions on genetic data exports and their impact on clinical trials.

China HealthcarePharmaceuticalsFDA Approval
12 min0 assets10 claims to verify
The East-West Bio Brief

Daily, Thu 12 Nov: A Shanghai pill wins FDA approval, after China said yes first

Episode discussion: Abbisko's pimicotinib wins FDA approval; Akeso/Summit awaits ivonescimab decision; Windward Bio files US IPO

Speakers’ claims: The hosts discuss Abbisko's pimicotinib receiving FDA approval for tenosynovial giant cell tumor, noting the trial's significant Chinese patient inclusion under Project AUBIS. They highlight Merck KGaA's commercial rights and the milestone payment structure. The episode covers the upcoming November 14 FDA decision for Akeso and Summit's ivonescimab, focusing on the statistical significance of overall survival data. Additional topics include South Korea's new policy allowing travelers to import GLP-1 drugs, Windward Bio's US IPO filing, ImvivaBio's lupus CAR-T data, Shionogi's licensing deal in Singapore, and Neuralink's expanded PRIME 2 trial.

FDA ApprovalsBiotech IPOsGLP-1 Drugs
14 min1 assets10 claims to verify
All insights